Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9

Abstract Atherosclerotic cardiovascular disease is the main cause of mortality and morbidity in the world. Plasma levels of low density lipoprotein cholesterol (LDL-C) are positively correlated with the risk of atherosclerosis. High plasma LDL concentrations in patients with hypercholesterolemia lead to build-up of LDL in the inner walls of the arteries, which becomes oxidized and promotes the formation of foam cells, consequently initiating atherosclerosis. Plasma LDL is mainly cleared through the LDL receptor (LDLR) pathway. Mutations in the LDLR cause familiar hypercholesterolemia and increase the risk of premature coronary heart disease. The expression of LDLR is regulated at the transcriptional level via the sterol regulatory element binding protein 2 (SREBP-2) and at the posttranslational levels mainly through proprotein convertase subtilisin/kexin-type 9 (PCSK9) and inducible degrader of the LDLR (IDOL). In this review, we summarize the latest advances in the studies of PCSK9.

• Publication year

  2015

• Venue

  Journal of Biomedical Research

• Publication date

  2015-07-20

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.7555/JBR.29.20150067PMID 26445568PMCID 4585429
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Very low LDL‐C levels may safely provide additional clinical cardiovascular benefit: the evidence to date

  2016cited by this paper
• Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.

  2015cited by this paper
• Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

  2015cited by this paper
• Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

  2015cited by this paper
• Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts

  2014cited by this paper
• Preserved adrenal function in fully PCSK9-deficient subject.

  2014cited by this paper
• The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion.

  2014cited by this paper
• Targeting LDL: is lower better and is it safe?

  2014cited by this paper
• Characterization of the role of EGF-A of low density lipoprotein receptor in PCSK9 binding

  2013cited by this paper
• Inflammation in Atherosclerosis

  2012cited by this paper
• Interaction between the ligand-binding domain of the LDL receptor and the C-terminal domain of PCSK9 is required for PCSK9 to remain bound to the LDL receptor during endosomal acidification.

  2012cited by this paper
• Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR

  2012influential reference
• Role of the C-terminal domain of PCSK9 in degradation of the LDL receptors[S]

  2011cited by this paper
• Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH

  2011cited by this paper
• Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.

  2010cited by this paper
• Primary hypercholesterolaemia impairs glucose homeostasis and insulin secretion in low-density lipoprotein receptor knockout mice independently of high-fat diet and obesity.

  2010influential reference
• A Two-step Binding Model of PCSK9 Interaction with the Low Density Lipoprotein Receptor*

  2010cited by this paper
• The molecular basis of familial hypercholesterolemia in Lebanon: Spectrum of LDLR mutations and role of PCSK9 as a modifier gene

  2009cited by this paper
• Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice

  2009cited by this paper
• Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease

  2009cited by this paper
• LXR Regulates Cholesterol Uptake Through Idol-Dependent Ubiquitination of the LDL Receptor

  2009influential reference
• Degradation of LDLR protein mediated by 'gain of function' PCSK9 mutants in normal and ARH cells.

  2009cited by this paper
• The LDL receptor.

  2009influential reference
• Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation

  2009cited by this paper
• Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells*

  2009cited by this paper
• Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

  2008cited by this paper
• The activation and physiological functions of the proprotein convertases.

  2008cited by this paper
• Macrophages: An elusive yet emerging therapeutic target of atherosclerosis

  2008cited by this paper
• Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor

  2008cited by this paper
• Plasma PCSK9 levels are significantly modified by statins and fibrates in humans

  2008cited by this paper
• Annexin A2 Is a C-terminal PCSK9-binding Protein That Regulates Endogenous Low Density Lipoprotein Receptor Levels*

  2008cited by this paper
• Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment.

  2008cited by this paper
• Catalytic Activity Is Not Required for Secreted PCSK9 to Reduce Low Density Lipoprotein Receptors in HepG2 Cells*

  2007cited by this paper
• Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol.

  2007cited by this paper
• Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation*

  2007influential reference
• Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia

  2007cited by this paper
• Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.

  2006cited by this paper
• Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

  2006cited by this paper
• The Proprotein Convertase (PC) PCSK9 Is Inactivated by Furin and/or PC5/6A

  2006cited by this paper
• Lowering LDL--Not Only How Low, But How Long?

  2006influential reference
• The proprotein convertases and their implication in sterol and/or lipid metabolism

  2006cited by this paper
• Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment.

  2005cited by this paper
• Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.

  2005cited by this paper
• Wild-type PCSK9 inhibits LDL clearance but does not affect apoB-containing lipoprotein production in mouse and cultured cells Published, JLR Papers in Press, March 1, 2005. DOI 10.1194/jlr.M400396-JLR200

  2005cited by this paper
• Proprotein convertase subtilisin kexin 9: the third locus implicated in autosomal dominant hypercholesterolemia

  2005cited by this paper
• Cooperation between fixed and low pH-inducible interfaces controls lipoprotein release by the LDL receptor.

  2004cited by this paper
• NARC-1/PCSK9 and Its Natural Mutants

  2004cited by this paper
• Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia

  2004cited by this paper
• Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse Liver*

  2004cited by this paper
• Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype.

  2004cited by this paper
• ZYMOGEN CLEAVAGE AND EFFECTS ON THE LOW DENSITY LIPOPROTEIN (LDL) RECEPTOR AND LDL CHOLESTEROL

  2004cited by this paper
• The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation

  2003cited by this paper
• Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

  2003cited by this paper
• Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes

  2003cited by this paper
• Inflammation in atherosclerosis

  2002cited by this paper
• Structure of the LDL Receptor Extracellular Domain at Endosomal pH

  2002influential reference
• LDL receptor but not apolipoprotein E deficiency increases diet-induced obesity and diabetes in mice.

  2002influential reference
• Is the class A macrophage scavenger receptor (SR-A) multifunctional? - The mouse's tale.

  2001cited by this paper
• Implications for familial hypercholesterolemia from the structure of the LDL receptor YWTD-EGF domain pair

  2001cited by this paper
• Western-type diets induce insulin resistance and hyperinsulinemia in LDL receptor-deficient mice but do not increase aortic atherosclerosis compared with normoinsulinemic mice in which similar plasma cholesterol levels are achieved by a fructose-rich diet.

  1999influential reference
• Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery.

  1993cited by this paper
• Different combinations of cysteine-rich repeats mediate binding of low density lipoprotein receptor to two different proteins.

  1989cited by this paper
• Acid-dependent ligand dissociation and recycling of LDL receptor mediated by growth factor homology region

  1987cited by this paper

• microRNA-21 promotes dysregulated lipid metabolism and hepatocellular carcinoma

  2025cites this paper
• Structural Dynamics of LDL Receptor Interactions with E498A and R499G Variants of PCSK9

  2024cites this paper
• PCSK9 inhibitors: a patent review 2018-2023

  2024cites this paper
• Inflammation and Fatty Infiltration Correlates with Rotator Cuff Muscle Atrophy in Hypercholesterolemic Yucatan Microswine.

  2024cites this paper
• Effects of Serum Estradiol on Proprotein Convertase Subtilisin/Kexin Type 9 Levels and Lipid Profiles in Women Undergoing In Vitro Fertilization

  2024cites this paper
• Lovastatin for lowering lipids

  2023cites this paper
• Comparative effects of black pigmented and non-pigmented brown rice on hypolipidemic activity and their mechanisms of action in high fat diet-induced hamsters

  2022cites this paper
• Proprotein convertase subtilisin/kexin type 9 genetic screening using the vervet (Chlorocebus aethiops) model

  2022cites this paper
• Surf4, cargo trafficking, lipid metabolism, and therapeutic implications

  2022cites this paper
• PCSK9 Knockdown Can Improve Myocardial Ischemia/Reperfusion Injury by Inhibiting Autophagy

  2022cites this paper
• Hypolipidemic Activity of Medicinal Plants: An Overview

  2022cites this paper
• Lactobacillus johnsonii BFE6154 Ameliorates Diet-Induced Hypercholesterolemia

  2021cites this paper
• Nanochitosan Effect on Biomolecular, Hypolipidemic in Rats and Incorporation in Functional Yogurt.

  2021cites this paper
• Two putative probiotic strains improve diet‐induced hypercholesterolemia through modulating intestinal cholesterol uptake and hepatic cholesterol efflux

  2021cites this paper
• Heterozosity in LDLR rs2228671 and LDLR rs72658855 are associated with increased risk of developing Coronary artery disease in India -A case control study.

  2020cites this paper
• Extra Virgin Olive Oil Phenol Extracts Exert Hypocholesterolemic Effects through the Modulation of the LDLR Pathway: In Vitro and Cellular Mechanism of Action Elucidation

  2020cites this paper
• Lipid Transfer in Lipoprotein Metabolism and Cardiovascular Disease

  2020cites this paper
• Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism.

  2020cites this paper
• PCSK9 and LDL-C: The Role of Exercise

  2020cites this paper
• Rare Diseases Related with Lipoprotein Metabolism.

  2020cites this paper
• Autocrine effects of PCSK9 on cardiomyocytes

  2020cites this paper
• Therapeutic targets of hypercholesterolemia: HMGCR and LDLR Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

  2019cites this paper
• Cholesterol transport system: An integrated cholesterol transport model involved in atherosclerosis.

  2019cites this paper
• Therapeutic targets of hypercholesterolemia: HMGCR and LDLR

  2019cites this paper
• Identification of Proteins Interacting with PCSK9 Using a Protoarray Human Protein Microarray

  2019cites this paper
• Preparation of a Functional Rat LDL Receptor Minigene

  2019cites this paper
• Proprotein convertase subtilisin/kexin type 9 inhibits interferon β expression through interacting with ATF‐2

  2018cites this paper
• Advancement in nanotechnology-based approaches for the treatment and diagnosis of hypercholesterolemia

  2018cites this paper
• Mutational analysis of the LDLR gene in a cohort of Colombian families with familial hypercholesterolemia.

  2018cites this paper
• PCSK9-related LDL-C value is correlated to Rab5 isoform expression level

  2017cites this paper
• Synergistic effect of scavenger receptor A and low-density lipoprotein receptor on foam cell formation

  2017cites this paper
• A method of rapid rabbit atherosclerosis model establishment

  2017cites this paper
• Proteins Interacting with PCSK 9 : A Potential for Personalized Medicine

  2017cites this paper
• Treating Human Hepatocyte-like C 3 A Cells with Estrogen , Thyroid Hormone , and Insulin Reduced the Ability of PCSK 9 to Form Complexes with the LDL Receptor

  2017cites this paper
• Hypercholesterolemia: The role of PCSK9.

  2017cites this paper
• Targeting pro-protein convertase subtilisin kexin-9 as a novel therapy of hypercholesterolemia

  2017cites this paper
• Synergistic Cardioprotective Effects of Combined Chromium Picolinate and Atorvastatin Treatment in Triton X-100-Induced Hyperlipidemia in Rats: Impact on Some Biochemical Markers

  2017cites this paper
• Hypocholesterolaemic Activity of Lupin Peptides: Investigation on the Crosstalk between Human Enterocytes and Hepatocytes Using a Co-Culture System Including Caco-2 and HepG2 Cells

  2016cites this paper
• Serum sdLDL-C and Cellular SREBP2-dependent Cholesterol Levels; is there a Challenge on Targeting PCSK9?

  2016cites this paper
• Lupin protein exerts cholesterol-lowering effects targeting PCSK9: From clinical evidences to elucidation of the in vitro molecular mechanism using HepG2 cells

  2016cites this paper
• Very low LDL‐C levels may safely provide additional clinical cardiovascular benefit: the evidence to date

  2016cites this paper
• Hypolipidemic Effect of Tomato Juice in Hamsters in High Cholesterol Diet-Induced Hyperlipidemia

  2015cites this paper
• FACULTAD DE FARMACIA UNIVERSIDAD COMPLUTENSE

  2015cites this paper